Cancer Chemotherapy and Pharmacology

, Volume 29, Issue 2, pp 89–94 | Cite as

Affinity of antineoplastic amino acid drugs for the large neutral amino acid transporter of the blood-brain barrier

  • Yoshiaki Takada
  • Nigel H. Greig
  • David T. Vistica
  • Stanley I. Rapoport
  • Quentin R. Smith
Original Articles Blood Brain Barrier, Amino Acid Transport, Brain Tumor

Summary

The relative affinity of six anticancer amino acid drugs for the neutral amino acid carrier of the blood-brain barrier was examined in rats using an in situ brain perfusion technique. Affinity was evaluated from the concentration-dependent inhibition ofl-[14C]-leucine uptake into rat brain during perfusion at tracer leucine concentrations and in the absence of competing amino acids. Of the six drugs tested, five, including melphalan, azaserine, acivicin, 6-diazo-5-oxo-l-norleucine, and buthionine sulfoximine, exhibited only low affinity for the carrier, displaying transport inhibition constants (Ki, concentrations producing 50% inhibition) ranging from 0.09 to 4.7 mM. However, one agent −d,l-2-amino-7-bis[(2-chloroethyl)amino]-1,2,3,4-tetrahydro-2-naphthoic acid (d,l-NAM) — demonstrated remarkably high affinity for the carrier, showing aKi value of ∼0.2 μM. The relative affintty (1/Ki) ofd,l-NAM was >100-fold that of the other drugs and >10-fold that of any compound previously tested. As the blood-brain barrier penetrability of most endogenous neutral amino acids is related to their carrier affinity, the results suggest thatd,l-NAM may be a promising agent which may show enhanced uptake and distribution to brain tumors.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Begleiter A, Lam H, Grover J, Froese E, Goldenberg G (1979) Evidence for active transport of melphalan by amino acid carriers in L5178Y lymphoblasts in vitro. Cancer Res 39: 353–359Google Scholar
  2. 2.
    Bennett LL (1975) Grutamine antagonists. In: Sartorelli AC, Johns DG (eds) Antineoplastic and immunosuppressive drugs, part II. Springer Verlag, Berlin, Heidelberg New York, pp 484–511Google Scholar
  3. 3.
    Brightman MW (1977) Morphology of blood-brain interfaces. Exp Eye Res [Suppl]: 1–25Google Scholar
  4. 4.
    Chastain JE, Borchardt RT (1990) Acivicin transport across bovine brain microvessel endothelial cell monolayers: a model of the blood-brain barrier. Neurosci Res Commun 6: 51–55Google Scholar
  5. 5.
    Cornford EM, Oldendorf WH (1975) Independent blood-brain barrier transport systems for nucleic acid precursors. Biochim Biophys Acta 394: 211–219Google Scholar
  6. 6.
    Fekete I, Griffith OW, Schlageter KE, Bigner DD, Friedman HS, Groothuis DR (1990) Rate of buthionine sulfoximine entry into brain and xenotransplanted human gliomas. Cancer Res 50: 1251–1256Google Scholar
  7. 7.
    Fisher B, Carbone P, Economons S (1975)l-Phenylalanine mustard in the management of primary breast cancer. N Engl J Med 292: 117–122Google Scholar
  8. 8.
    George RP, Poth JL, Gordon D, Schrier SL (1977) Multiple myeloma-intermittent combination chemotherapy compared to continuous therapy. Cancer 29: 1665–1670Google Scholar
  9. 9.
    Greig NH (1989a) Drug delivery to the brain by blood-brain barrier circumvention and drug modification. In: Neuwelt EA (ed) Implications of the blood-brain barrier and its manipulation, vol 1. Plenum Press, New York, pp 311–367Google Scholar
  10. 10.
    Greig NH (1989b) Brain tumors and the blood-tumor barrier. In: Neuwelt EA (ed) Implications of the blood-brain barrier and its manipulation, vol 2. Plenum Press, New York, pp 77–106Google Scholar
  11. 11.
    Greig NH, Momma S, Sweeney DJ, Smith QR, Rapoport SI (1987) Facilitated transport of melphalan at the rat blood-brain barrier by the large neutral amino acid carrier system. Cancer Res 47: 1571–1576Google Scholar
  12. 12.
    Griffith OW (1982) Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. J Biol Chem 257: 13704–13712Google Scholar
  13. 13.
    Groothuis DR, Molnar P, Blasberg RG (1984) Regional blood flow and blood-to-tissue transport in five brain tumor models. Prog Exp Tumor Res 27: 132–152Google Scholar
  14. 14.
    Haines DR, Fuller RW, Ahmad S, Vistica DT, Marquez VE (1987) Selective cytotoxicity of a System L specific amino acid nitrogen mustard. J Med Chem 30: 542–547Google Scholar
  15. 15.
    Hildebrand J (1985) Current status of chemotherapy of brain tumours. Prog Exp Tumor Res 29: 152–166Google Scholar
  16. 16.
    Huber KR, Rosenfeld H, Roberts J (1988) Uptake of glutamine antimetabolites 6-diazo-5-oxo-l-norleucine (DON) and, acivicin in sensitive and resistant tumor cell lines. Int J Cancer 41: 752–755Google Scholar
  17. 17.
    Kubo O, Himuro H, Inoue N, Tajika Y, Tohyama T, Sakairi M, Yoshida M, Kaetsu I, Kitamura K (1986) Treatment of malignant brain tumours with slow-releasing anticancer drug-polymer composites. No Shinkei Geka 14: 1189–1195Google Scholar
  18. 18.
    Leo A, Hansch C, Elkins D (1971) Partition coefficients and their uses. Chem Rev 71: 525–616Google Scholar
  19. 19.
    Levin VA (1987) Pharmacokinetics, and central nervous system chemotherapy. In: Hellmann K, Carter S (ed), Fundamentals of cancer chemotherapy. McGraw-Hill, New York, pp 28–40Google Scholar
  20. 20.
    Levin VA, Patak CS, Landahl HD (1980) Heuristic modeling of drug delivery to malignant brain tumors. J Pharmacokinet Biopharm 8: 257–296Google Scholar
  21. 21.
    Miller RG (1966) Simultaneous statistical inference. McGraw-Hill, New York, pp 76–81Google Scholar
  22. 22.
    Momma S, Aoyagi M, Rapoport SI, Smith QR (1987) Phenylalanine transport across the blood-brain barrier as studied with the in situ brain perfusion technique. J Neurochem 48: 1291–1300Google Scholar
  23. 23.
    Neuwelt EA, Dahlborg SA (1989) Blood-brain barrier disruption in the treatment of brain tumors: clinical implications. In: Neuwelt EA (ed) Implications of the blood-brain barrier and its manipulation, vol 2. Plenum Press, New York, pp 195–261Google Scholar
  24. 24.
    O'Dwyer PJ, Alonso MT, Leyland-Jones B (1984) Acivicin: a new glutamine antagonist in clinical trials. J Clin Oncol 2: 1064–1071Google Scholar
  25. 25.
    Oldendorf WH (1973) Stereospecificity of blood-brain barrier permeability to amino acids. Am J Physiol 224: 967–969Google Scholar
  26. 26.
    O'Tuama LA, Phillips PC, Strauss LC, Uno Y, Smith QR, Dannals RF, Wilson AA, Ravert HT, Lafrance ND, Wagner HN (1990) Two-phase [11C]-methionine PET scanning in the diagnosis of childhood brain tumors. Pediatr Neurol 6: 163–170Google Scholar
  27. 27.
    Oxender DL, Christensen HN (1963) Distinct mediating systems for the transport of neutral amino acids by the Ehrlich cell. J Biol Chem 238: 3686–3699Google Scholar
  28. 28.
    Pardridge WM (1977) Kinetics of competitive inhibition of neutral amino acid transport across the blood-brain barrier. J Neurochem 28: 103–108Google Scholar
  29. 29.
    Piver M, Barlow J, Lee F (1975) Sequential therapy for advanced ovarian adenocarcinoma: operation, chemotherapy, second-look laprotomy, and radiation therapy. Am J Obstet Gynecol 122: 355–357Google Scholar
  30. 30.
    Posner JB (1977) Management of central nervous system metastases. Semin Oncol 4: 81–91Google Scholar
  31. 31.
    Preston RL, Schaeffer JF, Curran PF (1974) Structure-affinity relationships of substrates for the neutral amino acid transport system in rabbit ileum. J Gen Physiol 64: 443–467Google Scholar
  32. 32.
    Rama B, Mandel T, Jansen J, Dingeldein E, Mennel HD (1987) The intraneoplastic chemotherapy in a rat brain tumour model utilizing methotrexate-polymethylmethacrylate pellets. Acta Neurochir 87: 70–75Google Scholar
  33. 33.
    Ricardi R, Bleyer WA, Poplack DG (1983) Enhancement of delivery of antineoplastic drugs into cerebrospinal fluid. In: Wood JH (ed) Neurobiology of cerebrospinal fluid, vol 2. Plenum Press, New York, pp 453–466Google Scholar
  34. 34.
    Robinson PR, Rapoport SI (1990) Model of drug uptake by brain tumors: effects of osmotic treatment and of diffusion in brain. J Cereb Blood Flow Metab 10: 153–161Google Scholar
  35. 35.
    Schober O, Duden C, Meyer GJ, Muller JA, Hundeshagen H (1987) Non selective transport of [11C-methyl]-l-andd-methionine into a malignant glioma. Eur J Nucl Med 13: 103–105Google Scholar
  36. 36.
    Segal IH (1975) Enzyme kinetics. John Wiley and Sons, New York, pp 100–125Google Scholar
  37. 37.
    Smith QR, Takasato Y, Sweeney DJ, Rapoport SI (1985) Regional cerebrovascular transport of leucine as measured by the in situ brain perfusion technique. J Cereb Blood Flow Metab 5: 300–311Google Scholar
  38. 38.
    Smith QR, Momma S, Aoyagi M, Rapoport SI (1987) Kinetics of neutral amino acid transprot across the blood-brain barrier. J Neurochem 49: 1651–1658Google Scholar
  39. 39.
    Smith QR, Aoyagi SI, Rapoport SI (1989) Structural specificity of the brain capillary neutral amino acid transporter. Soc Neurosci Abstr 15: 1025Google Scholar
  40. 40.
    Spector R (1986) Nucleosice and vitamin homeostasis in the mammalian central nervous system. Ann NY Acad Sci 481: 221–230Google Scholar
  41. 41.
    Takasato Y, Rapoport SI, Smith SR (1984) An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am J Physiol 247: H484-H493Google Scholar
  42. 42.
    Tator CH, Wassenaar W (1977) Intraneoplastic injection of methotrexate for experimental brain-tumor chemotherapy. J Neurosurg 46: 165–174Google Scholar
  43. 43.
    Vistica DT (1983) Cellular pharmacokinetics of the phenylalanine mustards. Pharmacol Ther 22: 379–405Google Scholar
  44. 44.
    Vistica DT, Ahmad S, Fuller R, Hill J (1986) Transport and cytotoxicity of amino acid nitrogen mustards: implications for design of more selective antitumor agents. Fed Proc 45: 2447–2450Google Scholar
  45. 45.
    Williams MG, Earhart RH, Bailey H, McGovern JP (1990) Prevention of central nervous system toxicity of the antitumor antibiotic acivicin by concomitant infusion of an amino acid mixture. Cancer Res 50: 5475–5480Google Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • Yoshiaki Takada
    • 1
  • Nigel H. Greig
    • 1
  • David T. Vistica
    • 2
  • Stanley I. Rapoport
    • 1
  • Quentin R. Smith
    • 1
  1. 1.Laboratory of Neurosciences, National Institute on AgingNational Institute of HealthBethesdaUSA
  2. 2.Laboratory of Drug Discovery, Research and DevelopmentNational Cancer Institute, Frederick Cancer Research CenterFrederickUSA

Personalised recommendations